METHODS: We used a cryptorchid rat testes model of SSC disturbance. The model was generated using intra-abdominal injection of flutamide (7.5 mg/rat) into pregnant Sprague-Dawley rats. Normal testes, unilateral undescended testes (UDT), and contralateral descended testes (DT) were extirpated on postnatal day 9, when two types of SSCs (gonocytes and spermatogonia) co-existed and gonocytes began differentiation into spematogonia. A microarray examining DT and UDT focused on miR-135a, which exhibited lower expression in UDT. In situ hybridization (ISH) was used for the detection of the localization of miR-135a and quantitative polymerase chain reaction (qPCR) to determine the organ specificity of the gene. We then searched the miR-135a target genes using a computer program, followed by the luciferase assay to demonstrate the suppression effect of miR-135a in vitro.
INTRODUCTION AND OBJECTIVES:
Recently male late-onset hypogonadism syndrome (LOH syndrome) is focused on with various symptoms due to hypogonadism. Although the results of the differentiation instructions from human induced pluripotent stem cell (human iPS cells) to many various cells, there is no report that succeed in induced Leydig cell which secret androgens. In this time we succeeded in Induced Leydig cell secrete testosterone from human iPS cells.
METHODS: First, we transduced NR5A1 expressing system by doxycycline addition to human iPS cell. We examined various genetic expression and hormone producing ability and evaluate the differentiation instruction from this cell under a timing of the NR5A1 forced expression and various kinds of conditions. Human iPS cells-derived testosterone-producing Leydig cells were transplanted into castrated male rats and examined for improvement in serum testosterone levels.
RESULTS: Leydig cell marker (INSL3 variant2) and LH receptor (LHCGR) and Leydig cell-specific enzyme (17bHSD3)and expression of various enzyme (StAR,CYP11A,3bHSD2,CYP17A) necessary for testosterone production were confirmed in RT-PCR.INSL3 and LHCGR were confirmed in Immunohistochemical staining.Testosterone production was confirmed by the hormone measurement in supernatants. And we showed that transplantation of human iPS cells-derived testosterone-producing Leydig cells to castrated rats ameliorate serum testosterone levels.At the same time, expression of adrenal cortexspecific enzyme (CYP21A2,CYP11B1,CYP11B2) necessary for cortisol and aldosterone production were confirmed in RT-PCR. The cluster of Leydig cells include the adrenal cortex cells too.
CONCLUSIONS: We succeeded in Leydig cell instruction from human iPS cells. At the same time to adrenocortical cell is induced, and we will examine the specific differentiation instruction conditions to Leydig cell in future. Transplantation of human iPS cells-derived testosterone-producing Leydig cells to castrated rats ameliorate serum testosterone levels.
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PD33-11 PROGRESSIVE MUSCLE CELL DELIVERY AS A SOLUTION FOR VOLUMETRIC MUSCLE DEFECT REPAIR
Ji Hyun Kim, In Kap Ko, John Jackson, Anthony Atala, James Yoo*, Winston Salem, NC INTRODUCTION AND OBJECTIVES: Reconstructing functional volumetric tissue in vivo remains a critical challenge facing cellbased approaches. Several pre-vascularization approaches have been developed to increase cell viability following implantation. While structural and functional tissue restoration was achieved in preclinical rodent tissue defect models, the approaches used in these model fail to repair larger defects in a clinical setting. We propose an effective cell delivery system utilizing appropriate vascularization at the site of cell implantation that results in volumetric and functional tissue reconstruction.
METHODS: To demonstrate the feasibility of restoring functional volumetric tissues in the defect site, multiple, progressive delivery of cells was performed using ectopic cell transplantation in a subcutaneous site. Appropriate cell delivery parameters such as cell density, cell injection volume, and time interval between injections were tested. The efficiency of volumetric tissue formation was compared with single injection of the same number of cells that were used for multiple injections in ectopic and in situ volumetric muscle loss models. Histological and functional recovery was evaluated to determine the possibility for applications to treat critical-size muscle defects.
RESULTS: Multiple-cell injections with one-week interval between each injection resulted in an increased volume of the implants. Quantitatively, increased number of cell injections (up to 8 injections) correlated with an increased implant volume. Particularly, 6-8 cell injections demonstrated a statically significant difference when compared with 2-4 cell injections. The volumes of implants in all multiple, progressive cell injected groups showed a significant increase compared to the progressive gel only-injected groups (ANOVA, P<0.001). Histologically, an increase in the volume of reconstructed tissue formation was notable between 2 and 4 cell injections, but no significant size difference was observed beyond 4 cell injections. In each group, the newly formed tissue structures were skeletal muscle fibers as confirmed within the implant.
CONCLUSIONS: Progressive multiple cell injections yielded improved cell survival and formed volumetric muscle tissues in an ectopic muscle site. Results from this study suggest that this method can be used to repair volumetric tissue defects by overcoming diffusion limitations and facilitating adequate vascularization. 
PD33-12 IN VIVO EVALUATION OF FUNCTIONALIZED MUSCLE SCAFFOLDS FOR RECONSTRUCTION
Lindsey Shapiro, Young Min Ju, John Jackson, James Yoo, Anthony Atala, Sang Jin Lee*, Winston Salem, NC INTRODUCTION AND OBJECTIVES: It has been demonstrated that almost every tissue in the body contains some type of stem or progenitor cells. These cells are believed to be part of underlying regenerative machinery that is responsible for daily maintenance and repair of injured tissue. The presence of an underlying regenerative mechanism in the form of tissue-specific stem and progenitor cells e654 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 
